RP Management Mulls $11-share bid for Elan

LONDON--Royalty Pharma Management LLC Monday announces an indicative bid for Elan Corporation PLC
ELN, -20.00%
a neuroscience focused biotechnology company, of $11 for every Elan Share and every Elan ADS, a 12.6% to the current enterprise value of Elan.

MAIN FACTS:

-RC Management approached the Chairman of Elan on Feb. 18, followed by a meeting on Feb. 20.

-While Royalty Pharma has not received a formal response to its proposal and has been unsuccessful in its efforts to engage with Elan since making the proposal, Royalty Pharma remains committed to working towards a recommended transaction.

-Possible offer represents a cash premium of 6.3% to the closing share price of Elan Stock on Feb. 15, of $10.35 on the New York Stock Exchange.

-Royalty Pharma plans to finance the possible offer through a combination of available cash and debt.

-Elan shares at 0852 GMT in London traded down 3.0 cents, or 0.4%, at EUR794.0, valuing the company at EUR4.74 billion.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.